SCHEMBL6570375

SCHEMBL6570375

CO[C@@H]1CCc2ccccc2C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP11B1 P15538 1/20 0.51
CYP11B2 P19099 1/20 0.51
CYP2B6 P20813 1/20 0.51
PLAU P00749 1/20 0.50
IDO1 P14902 2/20 0.48
MTNR1A P48039 2/20 0.43
MTNR1B P49286 2/20 0.43
HTR1A P08908 1/20 0.43
HTR2C P28335 1/20 0.43
SLC6A4 P31645 1/20 0.43
HTR2B P41595 1/20 0.43
ANPEP P15144 1/20 0.43
ADRA1D P25100 1/20 0.42
ADRA1A P35348 1/20 0.42
ADRA1B P35368 1/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22524385 1.00 CYP1A2 (0.51) CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2
SCHEMBL6311069 1.00 CYP1A2 (0.51) CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2
SCHEMBL12348668 0.88 IDO1 (0.45) CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2
SCHEMBL1944510 0.84 IDO1 (0.58) CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2
SCHEMBL30275532 0.84 IDO1 (0.58) CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2
SCHEMBL11852553 0.83 PLAU (0.54) PLAUIDO1MTNR1AMTNR1BHTR1A
SCHEMBL8230626 0.79 IDO1 (0.72) PLAUIDO1MTNR1AMTNR1BHTR1A
SCHEMBL10447404 0.79 CYP1A2 (0.55) CYP1A2CYP11B1CYP11B2PLAUIDO1
SCHEMBL4529303 0.77 CYP11B2 (0.54) CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2
SCHEMBL18264462 0.77 FAAH (0.54) CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1089963-B1 HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE SMITHKLINE BEECHAM PLC (GB) 2004-06-16 EP disclosed
US-6458779-B1 TREATMENT OF CONDITIONS ASSOCIATED WITH EXCESS PRODUCTION OF SOLUBLE CD23 (S-CD23) SUCH AS AUTOIMMUNE DISEASE AND ALLERGY. THE COMPOUNDS OF THE INVENTION ARE ALSO INHIBITORS OF THE RELEASE OF TUMOUR NECROSIS FACTOR (TNF). SMITHKLINE BEECHAM P.L.C. (GB) 2002-10-01 US disclosed